Screener
Bristol-Myers Squibb BMY Alliance and other revenues — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net product sales | $12,588 | $11,909 | $23,756 | $22,794 |
| Alliance and other revenues | 385 | 360 | 706 | 676 |
| Total Revenues | 12,973 | 12,269 | 24,462 | 23,470 |
| Cost of products sold(a) | 3,726 | 3,372 | 7,146 | 6,404 |
| Selling, general and administrative | 1,826 | 1,713 | 3,443 | 3,297 |
| Research and development | 2,959 | 2,580 | 5,608 | 4,837 |
| Acquired IPRD | — | 1,508 | 94 | 1,695 |
| Amortization of acquired intangible assets | 437 | 830 | 874 | 1,660 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's alliance and other revenues — total revenues?
- Bristol-Myers Squibb (BMY) reported alliance and other revenues — total revenues of $385M in Q2 2026.
- How has Bristol-Myers Squibb's alliance and other revenues — total revenues changed year-over-year?
- Bristol-Myers Squibb's alliance and other revenues — total revenues increased by 6.9% year-over-year, from $360M to $385M.
- What is the long-term trend for Bristol-Myers Squibb's alliance and other revenues — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's alliance and other revenues — total revenues has grown at a 2.0% compound annual growth rate (CAGR), from $1.33B to $1.44B.
- What does alliance and other revenues — total revenues mean?
- This metric represents revenue generated from collaborative arrangements, profit-sharing agreements, and royalty streams derived from partnerships with other pharmaceutical or biotechnology companies. It captures the financial benefit of co-development or co-commercialization efforts where the company does not hold full ownership of the underlying product. This revenue stream is critical for assessing the value of the company's external innovation pipeline and its ability to monetize intellectual property through strategic alliances.
Ask your AI about Bristol-Myers Squibb's alliance and other revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude